A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, Hussein A. Abbas, Sanam Loghavi, Gautam Borthakur, Musa Yilmaz, Ghayas C. Issa, Samuel I. Dara, Mahesh Basyal, Li Li, Kiran Naqvi, Rasoul Pourebrahim, Elias J. Jabbour, Steven M. Kornblau, Nicholas J. Short, Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi, Joseph KhouryNaval Daver, Hagop M. Kantarjian, Michael Andreeff, Courtney D. DiNardo

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences